Axsome Beats Securities Suit Over Migraine Drug, For Now
A New York federal judge on Monday tossed a proposed securities class action alleging that biopharmaceutical company Axsome hid issues about its migraine drug, leading to a significant stock price drop,...To view the full article, register now.
Already a subscriber? Click here to view full article